A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli
NCT00724919
Last updated date
ABOUT THIS STUDY
To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post-
intervention in the selected medical centres
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
InfectionVoriconazole as Prophylactic Therapy in Lung Transplant Recipients
NCT00455364
- Chicago, Illinois
ALL GENDERS
18 Years+
years
MULTIPLE SITES
InfectionMDR Bacilli Surveillance and Clinical Feature in China
NCT02140853
- Guangzhou, Guangdong
ALL GENDERS
18 Years+
years
MULTIPLE SITES
InfectionA Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli
NCT00724919
- Miaoli County,
- Taichung,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
InfectionStudy Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women
NCT00751764
- Plymouth,
Female
21 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli | |||
| Official Title | Association of Antibiotic Utilization Measures and Control of Extended-Spectrum ?-Lactamases (ESBLs) (A Post-Intervention Surveillance Study) | |||
| Brief Summary | To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres | |||
| Detailed Description | This is post-interventional study to follow the acquisition rate of ESBP producing E. coli or K. pneumoniae at the sites involved in a previous interventional study. | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Cohort Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Non-Probability Sample | |||
| Study Population | patients admitted to ICU/burn unit | |||
| Condition | Infection | |||
| Intervention | Not Provided | |||
| Study Groups/Cohorts | 1 | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 256 | |||
| Original Actual Enrollment | Same as current | |||
| Actual Study Completion Date | April 2004 | |||
| Actual Primary Completion Date | April 2004 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion
Patients were excluded if they had underlying conditions or diseases that were ultimately fatal within 48 hours | |||
| Sex/Gender |
| |||
| Ages | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Taiwan | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00724919 | |||
| Other Study ID Numbers | 0910X-101440 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth | |||
| Study Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Verification Date | August 2008 | |||